Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus Aureus

Trial Profile

Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus Aureus

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Brilacidin (Primary) ; Daptomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors PolyMedix
  • Most Recent Events

    • 21 Sep 2015 Results assessing population pharmacokinetics presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
    • 21 Sep 2015 Population pharmacokinetics analysis results from this trial and an another trial presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy.
    • 26 Jan 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2011-003741-17).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top